Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.

被引：0
|
作者：
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Llimpe, F. L. Rojas
Ceccarelli, C.
Mutri, V.
Giaquinta, S.
Piana, E.
Martoni, A. A.
机构：
[1] S Orsola M Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[2] Osped Niguarda Ca Granda, Med Oncol Unit, Milan, Italy
[3] Torrette Hosp, Med Oncol Unit, Ancona, Italy
[4] S Orsola M Malpighi Hosp, Pathol Unit, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页码：186S / 186S
页数：1
相关论文
共 50 条
  • [1] Cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of folcetux phase II study
    Di Fabio, Francesca
    Pinto, Carmine
    Siena, Salvatore
    Cascinu, Stefano
    Ceccarelli, Claudio
    Llimpe, Fabiola Lorena Rojas
    Mutri, Vita
    Giaquinta, Stefania
    Piana, Edera
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2006, 17 : 309 - 310
  • [2] Phase II study of cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results (FOLCETUX study)
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Rojas Llimpe, F. L.
    Ceccarelli, C.
    Mutri, V
    Giaquinta, S.
    Piana, E.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI54 - XI55
  • [3] Cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastrooesophageal junction (GEJ) adenocarcinoma: Preliminary results of the italian phase II study
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Rojas, Llimpe F.
    Ceccarelli, C.
    Mutri, V
    Giaquinta, S.
    Piana, E.
    Martoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 97 - 97
  • [4] Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Llimpe, F. L. Rojas
    Ceccarelli, C.
    Mutri, V.
    Giannetta, L.
    Giaquinta, S.
    Funaioli, C.
    Berardi, R.
    Longobardi, C.
    Piana, E.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2007, 18 (03) : 510 - 517
  • [5] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Cascinu, S.
    Rojas, Llimpe F.
    Artale, S.
    Schinzari, G.
    Giaquinta, S.
    Mutri, V
    Martoni, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
  • [6] Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Llimpe, F. L. Rojas
    Cascinu, S.
    Giaquinta, S.
    Schinzari, G.
    Mutri, V.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study.
    Di Fabio, F.
    Pinto, C.
    Fanti, S.
    Llimpe, F. L. Rojas
    Longobardi, C.
    Nanni, C.
    Funaioli, C.
    Ambrosini, V.
    Sperandi, F.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 193S - 193S
  • [8] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur Gregory Ang
    Mulder, Karen E.
    Brezden-Masley, Christine
    Vickers, Michael M.
    Monzon, Jose Gerard
    Kennecke, Hagen F.
    Goel, Rakesh
    Ghosh, Sunita
    Marginean, Horia
    Vos, Larissa Joy
    Raynard, SeeSee Juliana
    Young, Kristine Lee
    Fields, Anthony L. A.
    Maroun, Jean Alfred
    Spratlin, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Arthur Lui
    Karen Mulder
    Christine Brezden-Masley
    Michael Vickers
    Jose Monzon
    Hagen Kennecke
    Rakesh Goel
    Larissa Vos
    Sunita Ghosh
    Horia Marginean
    Anthony Fields
    Jean Maroun
    Jennifer Spratlin
    Investigational New Drugs, 2018, 36 : 674 - 682
12345